gms | German Medical Science

10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010)

Deutsche Gesellschaft für Infektiologie,
Deutsche AIDS-Gesellschaft,
Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit,
Paul-Ehrlich-Gesellschaft für Chemotherapie

23.06. - 26.06.2010, Köln

Soluferon® – next generation of a Type-1 interferon to treat virus infection

Soluferon® – ein Typ-1 Interferonder nächsten Generation zur Behandlung viraler Infektionen

Meeting Abstract

  • L. Grode - Vakzine Projekt Management GmbH, Hannover, Germany
  • C. Oertelt - Vakzine Projekt Management GmbH, Hannover, Germany
  • H.-H. Henneicke-von Zepelin - Vakzine Projekt Management GmbH, Hannover, Germany
  • B. Eisele - Vakzine Projekt Management GmbH, Hannover, Germany

10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010). Köln, 23.-26.06.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. DocP104

DOI: 10.3205/10kit159, URN: urn:nbn:de:0183-10kit1593

Veröffentlicht: 2. Juni 2010

© 2010 Grode et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Soluferon® is a 2nd generation modified interferon-β (IFN-β) with increased bioavailability, due to enhanced hydrophilic properties. It is well known that the major shortcomings of the currently marketed interferon-ß, namely limited efficacy and tolerability, have been attributed to their high hydrophobicity causing aggregation and antigenicity.

In order to improve the pharmacokinetic properties of Soluferon® the amino acid sequence of human interferon-β was changed. In the non-functional portion of the molecule, eight hydrophobic amino acids and one cystein were replaced by hydrophilic serine moieties. As a result hydrophobicity was reduced and bioavailability was increased up to six-fold when compared to human interferon-β. As Soluferon® belongs to the Type-I interferon family, it was hypothesised that, among other beneficial effects, Soluferon® has antiviral activity.

Preclinical studies support this thesis: Soluferon® inhibits the infection of human cells with Adenovirus. This effect is dose-independent. It also blocks dose-dependent proliferation of Coxsackie Virus, EMCV and Poliovirus. Furthermore, Soluferon® and Rebif, the positive control, induce IFN-susceptible gene expression for MxA protein in human cells, starting already at a concentration of 5 U/ml. They were also shown to activate IFN-susceptible gene factor dependent promotors with a similar efficiency. Already low doses of Soluferon showed a strong (10 to 60-fold) inhibitory effect on multiplication of influenza virus (H1N1) in human cells.

Moreover, tests in non-human primates showed promising results regarding pharmacodynamic parameters, e.g. 2'-5'-OAS.

These results state that great success can be achieved by the development and marketing of Soluferon® for antiviral therapy.